Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach

Reimund, Mart; Wolska, Anna; Risti, Robert; Wilson, Sierra; Sviridov, Denis; Remaley, Alan T.; Lóokene, Aivar

doi:10.1016/j.bbrc.2019.08.130

Cited by 15 publications

(11 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The 18A-C-II-a peptide enhances lipolysis in plasma from patients with ApoC-II deficiency and with other forms of hypertriglyceridemia in ex vivo studies [63]. This peptide also stimulates LPL activity in isolated lipoproteins [42]. In addition, 18A-C-II-a peptide strongly reduced plasma TG levels in different animal models, including apoC-II-KO zebrafish [64], ApoE-deficient mice [22], and ApoC-II-mutant mice [65].…”

Section: Apoc-ii-based Peptidesmentioning

confidence: 99%

“…A novel human ApoC-II mimetic bihelical peptide, C-II-a has recently been developed. Peptide C-II-a is formed by an amphipathic helix that contains the amino acid sequence of 18A peptide (ApoA-I-based peptide that confers cholesterol efflux stimulating properties) and a motif based on the last helix of apolipoprotein C-II (that activates LpL-induced lipolysis) [42].…”

Section: Apoc-ii-based Peptidesmentioning

confidence: 99%

See 1 more Smart Citation

Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis

Amaro

Curco²,

García

et al. 2021

JCM

View full text Add to dashboard Cite

Apolipoprotein (Apo)-based mimetic peptides have been shown to reduce atherosclerosis. Most of the ApoC-II and ApoE mimetics exert anti-atherosclerotic effects by improving lipid profile. ApoC-II mimetics reverse hypertriglyceridemia and ApoE-based peptides such as Ac-hE18A-NH2 reduce cholesterol and triglyceride (TG) levels in humans. Conversely, other classes of ApoE and ApoA-I mimetic peptides and, more recently, ApoJ and LRP1-based peptides, exhibit several anti-atherosclerotic actions in experimental models without influencing lipoprotein profile. These other mimetic peptides display at least one atheroprotective mechanism such as providing LDL stability against mechanical modification or conferring protection against the action of lipolytic enzymes inducing LDL aggregation in the arterial intima. Other anti-atherosclerotic effects exerted by these peptides also include protection against foam cell formation and inflammation, and induction of reverse cholesterol transport. Although the underlying mechanisms of action are still poorly described, the recent findings suggest that these mimetics could confer atheroprotection by favorably influencing lipoprotein function rather than lipoprotein levels. Despite the promising results obtained with peptide mimetics, the assessment of their stability, atheroprotective efficacy and tissue targeted delivery are issues currently under progress.

show abstract

Section: Apoc-ii-based Peptidesmentioning

confidence: 99%

Section: Apoc-ii-based Peptidesmentioning

confidence: 99%

Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis

Amaro

Curco²,

García

et al. 2021

JCM

View full text Add to dashboard Cite

show abstract

“…[ 164,165,167 ] As a result, it has been proposed that ApoC2 facilitates substrate interaction with LPL. [ 34,168,169 ]…”

Section: Apolipoproteins Modulating Lpl Activitymentioning

confidence: 99%

“…[ 176 ] These observations are consistent with biochemical studies that have described a paradoxical inhibition of LPL activity that occurs with high concentrations of ApoC2. [ 168 ]…”

Section: Apolipoproteins Modulating Lpl Activitymentioning

confidence: 99%

“…[164,165,167] As a result, it has been proposed that ApoC2 facilitates substrate interaction with LPL. [34,168,169] It has also been well documented that ApoC2 deficiency can cause severe hypertriglyceridemia, including familial chylomicronemia syndrome (FCS). [158,[170][171][172][173][174] In addition, autoantibodies directed against ApoC2 can lead to hypertriglyceridemia.…”

Section: Apoc2mentioning

confidence: 99%

See 1 more Smart Citation

The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity

2022

View full text Add to dashboard Cite

Triacylglycerol (TG) metabolism is tightly regulated to maintain a pool of TG within circulating lipoproteins that can be hydrolyzed in a tissue‐specific manner by lipoprotein lipase (LPL) to enable the delivery of fatty acids to adipose or oxidative tissues as needed. Elevated serum TG concentrations, which result from a deficiency of LPL activity or, more commonly, an imbalance in the regulation of tissue‐specific LPL activities, have been associated with an increased risk of atherosclerotic cardiovascular disease through multiple studies. Among the most critical LPL regulators are the angiopoietin‐like (ANGPTL) proteins ANGPTL3, ANGPTL4, and ANGPTL8, and a number of different apolipoproteins including apolipoprotein A5 (ApoA5), apolipoprotein C2 (ApoC2), and apolipoprotein C3 (ApoC3). These ANGPTLs and apolipoproteins work together to orchestrate LPL activity and therefore play pivotal roles in TG partitioning, hydrolysis, and utilization. This review summarizes the mechanisms of action, epidemiological findings, and genetic data most relevant to these ANGPTLs and apolipoproteins. The interplay between these important regulators of TG metabolism in both fasted and fed states is highlighted with a holistic view toward understanding key concepts and interactions. Strategies for developing safe and effective therapeutics to reduce circulating TG by selectively targeting these ANGPTLs and apolipoproteins are also discussed.

show abstract

Calorimetric approach for comparison of Angiopoietin-like protein 4 with other pancreatic lipase inhibitors

Villo

Risti

Reimund

et al. 2020

Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biolog

View full text Add to dashboard Cite

Apolipoprotein C-II mimetic peptide is an efficient activator of lipoprotein lipase in human plasma as studied by a calorimetric approach

Cited by 15 publications

References 23 publications

Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis

Apolipoprotein and LRP1-Based Peptides as New Therapeutic Tools in Atherosclerosis

The Regulation of Triacylglycerol Metabolism and Lipoprotein Lipase Activity

Calorimetric approach for comparison of Angiopoietin-like protein 4 with other pancreatic lipase inhibitors

Contact Info

Product

Resources

About